SCHEMBL23273674

SCHEMBL23273674

CCOC(=O)c1cnn(CC)c1OCC

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.52
LMNA P02545 2/20 0.52
PDE4B Q07343 6/20 0.50
RAB9A P51151 3/20 0.49
KDM4E B2RXH2 1/20 0.49
PDE5A O76074 1/20 0.48
ALDH1A1 P00352 3/20 0.48
KMT2A Q03164 3/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HPGD P15428 3/20 0.48
TSHR P16473 1/20 0.47
MEN1 O00255 1/20 0.47
MAPT P10636 1/20 0.47
BLM P54132 1/20 0.47
PMP22 Q01453 1/20 0.47
TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1198982 0.87 NPC1 (0.49) NPC1LMNAPDE4BRAB9AKDM4E
SCHEMBL15436730 0.83 NPC1 (0.46) NPC1LMNAPDE4BRAB9AKDM4E
SCHEMBL1198694 0.83 NPC1 (0.49) NPC1LMNARAB9AKDM4EALDH1A1
SCHEMBL3265402 0.83 SMN1; SMN2 (0.60) NPC1LMNAPDE4BRAB9AALDH1A1
SCHEMBL9199014 0.83 LMNA (0.50) NPC1LMNAPDE4BRAB9AKDM4E
SCHEMBL3261727 0.83 RAB9A (0.50) NPC1LMNARAB9AKDM4EALDH1A1
SCHEMBL13462878 0.82 SMN1; SMN2 (0.58) NPC1LMNAPDE4BRAB9AKDM4E
SCHEMBL1458234 0.81 LMNA (0.51) NPC1LMNAPDE4BRAB9AKDM4E
SCHEMBL26102129 0.81 LMNA (0.51) NPC1LMNAPDE4BRAB9AKDM4E
SCHEMBL173434 0.79 NPC1 (0.68) NPC1LMNARAB9AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114761397-B Benzodiazepine derivatives for the treatment of Respiratory Syncytial Virus (RSV) infection 辉瑞公司 2024-11-05 CN disclosed
US-20220409629-A1 BENZODIAZEPINE DERIVATIVES FOR TREATING A RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION PFIZER INC. 2022-12-29 US disclosed
EP-4048665-A1 BENZODIAZEPINE DERIVATIVES FOR TREATING A RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION Reviral Limited (GB) 2022-08-31 EP disclosed
CN-114761397-A Benzodiazepine derivatives for the treatment of Respiratory Syncytial Virus (RSV) infection 瑞威有限公司 2022-07-15 CN disclosed
WO-2021079121-A1 BENZODIAZEPINE DERIVATIVES FOR TREATING A RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION ReViral Limited (GB) 2021-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220409629-A1 BENZODIAZEPINE DERIVATIVES FOR TREATING A RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION GABRA1, GABRA3, CNR1 NPC1 882/4885LMNA 2278/4885PDE4B 4062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.